Zobrazeno 1 - 10
of 245
pro vyhledávání: ''
Autor:
Manon Reda, Pauline Macaire, Hélène Bellio, Lionel Uwer, Silvia Ilie, Véronique Lorgis, Audrey Hennequin, Sylvain Ladoire, Emilie Rederstorff, Pierre Fumoleau, Nicolas Isambert, Nathalie Bonnin, Benoit You, Gilles Freyer, Isabelle Desmoulins, Antonin Schmitt
Publikováno v:
Cancer Chemotherapy and Pharmacology. 89:197-208
Granulocyte colony-stimulating factors (G-CSF) are commonly given to limit chemotherapy-induced neutropenia, but, in case of weekly chemotherapy such as eribulin, their administration schedules remain empirical.This pharmacokinetic/pharmacodynamic (P
Autor:
Nancy Chan, Jiuping Ji, Antoinette R. Tan, Janice M. Mehnert, Alice P. Chen, Jan H. Beumer, Mansi Shah, Joseph Aisner, Murugesan Gounder, Jyoti Malhotra, Rebecca A. Moss, Yong Lin, Brian F. Kiesel, Hongxia Lin, Mark N. Stein, Michael P. Kane
Publikováno v:
Cancer Chemother Pharmacol
Purpose Veliparib (V), an oral poly(ADP-ribose) polymerase (PARP) inhibitor, potentiates effects of alkylating agents and topoisomerase inhibitors in preclinical tumor models. We conducted a phase I trial of V with iv cyclophosphamide (C) and V plus
Autor:
Takashi Kojima, Satoshi Fujii, Hiroyuki Daiko, Hisanaga Nomura, Tomonori Yano, Toshikatsu Kawasaki, Ken Demachi, Nobuo Mochizuki, Daiki Tsuji, Haruki Matsuzawa, Kunihiko Itoh
Publikováno v:
Cancer Chemotherapy and Pharmacology. 86:315-324
The combination of docetaxel, cisplatin and 5-fluorouracil (DCF) is a newly developed chemotherapy regimen for esophageal cancer. Severe neutropenia is dose-limiting toxicity of docetaxel and it is well known to be frequently occurred during DCF chem
Publikováno v:
Cancer Chemotherapy and Pharmacology. 85:113-119
To determine the maximum tolerated dose (MTD) and recommended dose (RD) of modified FLOT regimen (fluorouracil plus leucovorin, oxaliplatin and docetaxel) for treating Chinese patients with metastatic adenocarcinoma of stomach. Chinese patients with
Autor:
Stacie Peacock Shepherd, Hao Xiong, Silpa Nuthalapati, Christine K. Ratajczak, Sven Mensing, Rajeev M. Menon, Sven Stodtmann
Publikováno v:
Cancer Chemotherapy and Pharmacology. 84:977-986
Veliparib, a poly(ADP-ribose)-polymerase (PARP) 1 and 2 enzyme inhibitor, was administered at 120 mg twice daily (BID) for 7 days in a 21-day cycle with carboplatin/paclitaxel in the Phase 2 BROCADE study in patients with BRCA-deficient recurrent or
Autor:
Yasuhiro Kato, Kageaki Watanabe, Shoko Kawai, Makiko Yomota, Yukio Hosomi, Tatsuru Okamura, Yusuke Okuma
Publikováno v:
Cancer Chemotherapy and Pharmacology
Background Few studies have investigated the clinical efficacy of third- and later-line of chemotherapy after standard chemotherapy for previously treated advanced non-small cell lung cancer (NSCLC). We prospectively evaluated the efficacy and safety
Autor:
Keigo Hara, Makoto Sakai, Ken Shirabe, Hideyuki Saito, Tomonori Yoshida, Shin-ei Noda, Makoto Sohda, Takashi Nakano, Yuji Kumakura, Tatsuya Miyazaki, Kengo Kuriyama, Kazutoshi Murata, Takehiko Yokobori, Hiroyuki Kuwano
Publikováno v:
Cancer Chemotherapy and Pharmacology. 83:1121-1126
To evaluate the efficacy of docetaxel, cisplatin, and 5-fluorouracil as combination chemoradiotherapy (DCF-RT) for cervical esophageal cancer (CEC), we performed a retrospective analysis of CEC patients treated by DCF-RT at a single institution. We c
Autor:
Lin Yang, Chengxu Cui, Wen Zhang, Yongkun Sun, Aiping Zhou, Zhichao Jiang, Chengfeng Wang, Jinwang Wang, Chun-Xia Du
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose We conducted a single-arm prospective phase II study to determine the efficacy and safety of the first-line treatment of advanced pancreatic cancer with nab-paclitaxel and S-1 followed by S-1 maintenance therapy. Methods Nab-paclitaxel was ad
Autor:
Tomonobu Koizumi, Kazunari Tateishi, Tsutomu Hachiya, Takashi Kobayashi, Kei Sonehara, Fumiaki Yoshiike, Yuuki Wakatsuki, Manabu Yamamoto, Takeshi Masubuchi, Kazuya Hirai, Toshirou Fukushima
Publikováno v:
Cancer Chemotherapy and Pharmacology. 81:1043-1050
This phase II study was performed to evaluate the efficacy and safety of cisplatin/pemetrexed combined with 15 mg/kg of bevacizumab followed by pemetrexed/bevacizumab maintenance therapy as first-line chemotherapy in advanced non-squamous non-small c
Autor:
Qian Xu, Dongta Zhong, Yan-Qin Lan, Xinli Wang, Ri-ping Wu, Xin-yan Gao, Ling-jun Kong, Xiaoyan Lin
Publikováno v:
Cancer Chemotherapy and Pharmacology. 81:1007-1015
This study is a retrospective analysis evaluating the efficacy and toxicity of combination chemotherapy with Paclitaxel (PTX) and Oxaliplatin (OXA) as first-line treatment for patients with advanced gastric cancer (AGC). One hundred and seven patient